Skip to main content
KPRX
NASDAQ Life Sciences

Kiora In-Licenses Phase 3-Ready CRAO Drug KIO-401 for $3.5M Upfront, Up to $168.5M Milestones

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.58
Mkt Cap
$10.442M
52W Low
$1.765
52W High
$2.91
52W Position info
46% above low
Off High info
11% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

KPRX sits 46% above its 52-week low of $1.765 on elevated volume (1.9× avg).

Summary

Kiora licensed ex-Asia rights to Senju's Phase 3-ready oral calpain inhibitor KIO-401 for CRAO, paying $3.5M upfront plus a $12.5M technology-transfer milestone and up to $168.5M in later milestones. The company now needs to raise capital to fund the Phase 3 trial it targets for 2027.


Key Events · M&A and Partnerships · KPRX

  • Exclusive KIO-401 License Signed

    Kiora obtained exclusive development and commercialization rights to KIO-401 (mitucapistat), an oral calpain inhibitor, from Senju Pharmaceutical for all territories outside Asia, in the ophthalmology field.

  • Deal Economics: $3.5M Upfront

    Kiora pays $3.5M upfront, a $12.5M technology-transfer milestone (a portion creditable against future milestones), up to $168.5M in regulatory and commercial milestones, and single-digit royalties on net sales outside Asia.

  • Phase 3 Trial Targeted for 2027

    Senju completed Phase 2a and Phase 3 CRAO studies in Japan; Kiora plans a multinational Phase 3 registration trial of more than 100 patients starting in 2027, plus a Phase 2b NAION trial targeted for 2028.

  • Financing Needed to Fund Program

    Kiora states it is evaluating financing alternatives to fund KIO-401 development, and discontinued KIO-104 R&D to prioritize KIO-401 and partnered KIO-301.


Analysis · KPRX · Life Sciences

Kiora just bought itself a Phase 3-ready asset. Senju has already run Phase 2a and Phase 3 CRAO trials in Japan, so Kiora skips years of early work and goes straight to a multinational registration trial targeted for 2027. The catch is cash: $3.5M is due now, a low-teen-million payment (the agreement states $12.5M) comes at technology transfer, and the company says it is evaluating financing alternatives — on a company this small, that almost certainly means selling stock. The $168.5M in milestones and single-digit royalties only pay out years from now, if the drug works. KIO-104 was discontinued to concentrate resources here.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KPRX was trading at $2.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $1.76 to $2.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KPRX - Latest Insights

KPRX
Nov 12, 2026, 7:01 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.40
Real-time Price: $1.23 info
Change: -$0.170 (-12%) info
Market Cap: $5.442M info
KPRX
Aug 19, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $1.23 info
Change: -$1.42 (-54%) info
Market Cap: $5.442M info
KPRX
Aug 07, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.58
Real-time Price: $1.23 info
Change: -$1.35 (-52%) info
Market Cap: $5.442M info
KPRX
Jun 18, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.57
Real-time Price: $1.23 info
Change: -$1.34 (-52%) info
Market Cap: $5.442M info
KPRX
Jun 18, 2026, 7:00 AM EDT
Source: TMX Newsfile
Importance Score:
7
Price at Filing: $2.57
Real-time Price: $1.23 info
Change: -$1.34 (-52%) info
Market Cap: $5.442M info